Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes + Platinum in Recurrent SCLC
NCT06467786Phase 4Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of irinotecan liposome in small cell lung cancer (SCLC), sponsored by Tangdu Hospital. Started Mar 2024; status: recruiting.
02
Drugs
irinotecan liposome
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06467786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467786.